Outlook
2023
Annual Industry Ranking And Forecast
Research & Development
New data show that European pharma innovation is being edged into third place by innovation coming from the US and the new powerhouse of research, China.

Pharma Innovation: Europe Is Being Edged Into Third Place
With a declining share of global R&D and investment, Europe risks the pharmaceutical industry being increasingly molded in the image of others.

Growing Pains: Charting The Rapid Rise Of Chinese IO
Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade. This period has also witnessed a dramatic growth in China’s domestic pharmaceutical industry, and significant changes in the interaction between this industry and international pharma. This coalescence has led to excitement about the role that Chinese IO could play on the global stage, tempered by regulatory set-backs and revised marketing timelines.

Five Potential Blockbuster Oncology Approvals To Look Out For In 2023
With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.

Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s
Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.